The stock of Juno Therapeutics Inc (NASDAQ:JUNO) reached all time low today, Nov, 23 and still has $21.19 target or 5.00% below today’s $22.31 share price. This indicates more downside for the $2.24B company. This technical setup was reported by Barchart.com. If the $21.19 PT is reached, the company will be worth $112.00 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 6.47M shares traded hands or 346.21% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.60% since April 21, 2016 and is downtrending. It has underperformed by 37.93% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Suntrust Robinson initiated it with “Buy” rating and $50 target price in Friday, January 29 report. Standpoint Research initiated it with “Buy” rating and $47.0 target price in Monday, August 24 report. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Buy” rating given on Tuesday, December 15 by Standpoint Research. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Hold” rating by Standpoint Research on Thursday, October 29. The rating was initiated by Northland Capital with “Outperform” on Wednesday, July 22. FBR Capital maintained the stock with “Outperform” rating in Friday, July 8 report. The firm earned “Neutral” rating on Wednesday, November 18 by Goldman Sachs. The stock has “Buy” rating given by Citigroup on Thursday, February 25. On Friday, August 5 the stock rating was maintained by Maxim Group with “Buy”. FBR Capital initiated the shares of JUNO in a report on Tuesday, August 18 with “Outperform” rating.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Moreover, Parametric Assocs Limited Liability Corp has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 12,485 shares. Parametrica last reported 11,609 shares in the company. First Republic Management Inc reported 5,935 shares or 0% of all its holdings. California State Teachers Retirement System last reported 0.01% of its portfolio in the stock. Aqr Mngmt Limited Liability Company accumulated 0.02% or 232,432 shares. Rock Springs L P owns 197,001 shares or 0.56% of their US portfolio. Alliancebernstein Ltd Partnership reported 36,736 shares or 0% of all its holdings. Schwab Charles Investment Mngmt holds 234,448 shares or 0.01% of its portfolio. Winfield Associate Inc, a Ohio-based fund reported 20 shares. Bancorporation Of Montreal Can holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 38 shares. Checchi Cap Advisers has 162 shares for 0% of their US portfolio. Cap World Invsts, a California-based fund reported 3.64 million shares. Brighton Jones Limited Liability Corporation holds 0.04% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 6,379 shares. Benjamin F Edwards And Incorporated reported 2,960 shares or 0.02% of all its holdings. Moreover, Arrowpoint Asset Mgmt Ltd Liability Com has 0.41% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 526,717 shares.
More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Businesswire.com which released: “Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold” on November 23, 2016, also Fool.com published article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics”, Schaeffersresearch.com published: “Buzz Stocks: Juno Therapeutics Inc, Eli Lilly and Co, and Biogen Inc” on November 23, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Fool.com and their article: “Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals” with publication date: October 28, 2016.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.